SCHEMBL3273787

SCHEMBL3273787

O=C(/C=C/c1ccc(F)c(C(F)(F)F)c1)Nc1cc(Cl)ccc1-c1nnn[nH]1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.39
PKM P14618 1/20 0.39
MAOB P27338 1/20 0.39
TP53 P04637 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
HPSE Q9Y251 1/20 0.38
EGFR P00533 1/20 0.38
MAPT P10636 2/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
TRPA1 O75762 2/20 0.37
GAA P10253 1/20 0.37
KCNK2 O95069 1/20 0.36
MMP1 P03956 2/20 0.36
MMP2 P08253 2/20 0.36
MMP9 P14780 2/20 0.36
NPC1 O15118 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3273798 1.00 POLB (0.39) POLBPKMMAOBTP53SMN1; SMN2
SCHEMBL3273355 0.84 TP53 (0.45) PKMTP53EGFRMAPTMEN1
SCHEMBL3273349 0.84 TP53 (0.45) PKMTP53EGFRMAPTMEN1
SCHEMBL3272677 0.82 EGFR (0.44) MAOBTP53SMN1; SMN2EGFRMAPT
SCHEMBL3272673 0.82 EGFR (0.44) MAOBTP53SMN1; SMN2EGFRMAPT
SCHEMBL1308279 0.75 GRM5 (0.50) MEN1KMT2AKDM4EGAARAB9A
SCHEMBL3273777 0.74 EGFR (0.47) POLBMAOBTP53SMN1; SMN2EGFR
SCHEMBL3273782 0.74 EGFR (0.47) POLBMAOBTP53SMN1; SMN2EGFR
SCHEMBL3277357 0.73 TRPM2 (0.40) POLBPKMMAOBTP53EGFR
SCHEMBL3277364 0.73 TRPM2 (0.40) POLBPKMMAOBTP53EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100087496-A1 NOVEL CINNAMIC AMIDE DERIVATIVES USEFUL AS ION CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2010-04-08 US claimed
US-20100087496-A1 NOVEL CINNAMIC AMIDE DERIVATIVES USEFUL AS ION CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2010-04-08 US disclosed
EP-2121569-A2 NOVEL CINNAMIC AMIDE DERIVATIVES USEFUL AS ION CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2009-11-25 EP disclosed
WO-2008074755-A2 NOVEL CINNAMIC AMIDE DERIVATIVES USEFUL AS ION CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2008-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087496-A1 NOVEL CINNAMIC AMIDE DERIVATIVES USEFUL AS ION CHANNEL MODULATORS TRPV1, TRPA1, TRPM8 POLB 4833/4885PKM 3573/4885MAOB 3995/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.